Willis Towers Watson heads into its July 30 earnings date riding a 12.4% weekly gain to $293.90, with the Street sharpening its pencils and options traders rotating decisively toward calls.
The most striking shift this week is in analyst positioning. Bulls moved quickly on the rally: UBS raised its target to $382 from $374 today, and Keefe, Bruyette & Woods nudged theirs to $381 from $380 — both maintaining positive ratings. Barclays took the other side, cutting to $303 from $322 while staying at Equal-Weight, a signal that at least part of the Street sees the move as having run ahead of fundamentals. The consensus mean target is $333.52, now sitting below the current price when the more cautious targets pull it down, but the bull camp carries targets in the $380s — roughly 30% above where the stock trades today. Valuation has re-rated in tandem: the trailing P/E has compressed toward 12.3x as the earnings base has grown, while EV/EBITDA is running near 9.2x. Neither multiple looks stretched for a well-run insurance broker.
Options positioning backs the bullish tilt. The put/call ratio dropped to 0.70, a full standard deviation below its 20-day average of 0.85 — well toward the call-heavy end of the past year's range. That's a sharp rotation from where this ratio spent most of May and early June, when it was pinned above 1.0 for nearly six consecutive weeks. The shift from defensive hedging to outright call buying happened almost exactly when the stock began its latest leg higher in late June, and the two trends have reinforced each other since.
Short interest is building but not at a level that tells a threatening story. Shorts hold roughly 3.8% of the free float — up 24% over the past month in share terms but still modest in absolute terms. Borrow conditions offer no friction: availability is running near 973%, meaning shares to lend dwarf current borrowing demand by a factor of nearly ten. Cost to borrow has collapsed to 0.45% after briefly spiking to 7.2% on June 30 — an idiosyncratic one-day move that quickly unwound. The ORTEX short score is a relatively benign 41.9, and the short-score rank in the 27th percentile confirms there is no meaningful short-seller conviction building here.
The earnings history adds a note of caution. When WTW last reported on April 30, the stock fell 11.6% on the day and extended that to -11% over the following week. That reaction came despite what a recent note described as stronger-than-expected Q2 results — suggesting the market may have been positioned for even better. With the stock now 18% above that post-earnings low and peers AJG and AON also up roughly 12% and 10% on the week respectively, the sector tailwind appears broad-based rather than WTW-specific. Insider activity from early May is supportive context: the CEO bought $510,000 worth of stock at $255 and a divisional president added $499,000 at $263, both well below current levels.
What to watch into July 30 is whether the Street's bullish target revisions can close the gap to the $380s — or whether the Barclays cut to $303 proves the more prescient read on how much of the earnings story the market has already priced in.
See the live data behind this article on ORTEX.
Open WTW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
